Baekeland mandate for Parkinson's Disease drug discovery in our CRO

reMYND’s CRO unit and the Baekelandt lab will submit a Baekeland PhD project (Vlaio) for the development and validation of Parkinson’s disease models for drug discovery. We are currently looking for a motivated PhD student to embark on a 4-year PhD project. If you are interested visit:

Read more
Interreg. project "Memories" update

An intermediate update on the progress of identifying differently expressed microRNA in Alzheimer's Disease.

Read more
Interreg. project "Memories" holds 2nd annual symposium & new newsletter is available

The Interreg. Flanders-Netherlands project "Memories" (Dutch: "Herinneringen") will hold its 2nd annual Symposium on December 16th, 2019 in Leuven. The initial gathered data on activated mechanisms after addition of Alzheimer-related mechanisms will be presented. The intermediary update is available in the third newslette. Visit to receive the latest updates.

Read more
reMYND raises 12 million EUR to assess clinical proof-of-mechanism in Alzheimer’s and to expand into orphan disorders

Leuven Belgium, December 18th, 2018: reMYND NV announced today the closing of a 12 million EUR financing round to

  • advance its Alzheimer program into clinical testing and assess its novel mechanism in patients;
  • broaden the pipeline into CNS orphan programs, including Huntington and ALS;
  • further innovate and expand the service offering of its CRO;
  • and strengthen the executive team and board.
Read more
Approved project ‘Memories’: early diagnostics of Alzheimer’s disease (AD)

Interreg granted a positive ruling on the project ‘Memories’ mid-December. reMYND will team up with the consortium partners ToxGenSolutions, Icometrix, KU Leuven, Maastricht University and UAntwerpen to support AD research aimed at a sustainable, inclusive growth among Flanders and South-Netherlands. The entire project will receive almost € 800.000 in funding from Interreg. The province of Flemish Brabant will support the project with an additional sum of nearly € 150.000.

Read more
reMYND enters into license agreement to further develop novel treatments improving beta-cell health and insulin signalling with Novo Nordisk

Leuven Belgium, December 14th, 2017: reMYND and Novo Nordisk have entered into a license agreement to further develop reMYND’s ReS39 therapeutic program of diabetes. This program holds also promise for NASH and the metabolic syndrome.

Read more
reMYND signs the Statement in support of animal research and a transparent approach
reMYND, has joined with 21 other organisations from across the life sciences sector in signing up to a declaration on openness on animal research.
Read more
reMYND to present on Biotechdag
reMYND will be presenting on the research towards the treatment of Alheimers and diabetes worldwide.
Read more
IWT supports reMYND in developing a cure for Type 1 Diabetes
reMYND announced that it has received a grant from IWT to assess the potential of its Diabetes program in curing Type 1 Diabetes Mellitus (T1DM).
Read more
Roche and reMYND's DDD enter into a strategic alliance to develop first-in-class disease-modifying treatments for Parkinson's and Alzheimer's disease
Roche (SIX: RO, ROG; OTCQX: RHHBY) and reMYND today announced that they have entered into an agreement.
Read more